Aurelia Haller

USPTO Granted Patents = 15 (Patent Applications = 4)

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 1 (Patent Applications = 9)

Average Co-Inventor Count = 3.1

ph-index = 10

Forward Citations = 330(Granted Patents)

Location History:

Redwood City, CA (US) (2007 - 2014)
Boulder, CO (US) (2004 - 2016)

Company Filing History:

Medimmune Vaccines, Inc.

Erasmus University Medical Center Rotterdam

patents

where one patent can have more than one assignee

Years Active: 2004-2016

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9376726 - Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences (2016-06-28),

2. 8821892 - Yeast-based therapeutic for chronic hepatitis C infection (2014-09-02),

3. 8722341 - Metapneumovirus strains and their use in vaccine formulations and sequences (2014-05-13),

4. 8388980 - Yeast-based therapeutic for chronic hepatitis C infection (2013-03-05),

5. 8084037 - Recombinant parainfluenza virus expression systems and vaccines (2011-12-27),

6. 8007816 - Yeast-based therapeutic for chronic hepatitis C infection (2011-08-30),

7. 7736642 - Yeast-based vaccine for inducing an immune response (2010-06-15),

8. 7678376 - Recombinant parainfluenza virus expression systems and vaccines (2010-03-16),

9. 7632511 - Yeast-based therapeutic for chronic hepatitis C infection (2009-12-15),

10. 7625569 - Yeast-based therapeutic for chronic hepatitis C infection (2009-12-01),

11. 7531342 - Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences (2009-05-12),

12. 7439042 - Yeast-based therapeutic for chronic hepatitis C infection (2008-10-21),

13. 7341729 - Recombinant parainfluenza virus expression systems and vaccines (2008-03-11),

14. 7238481 - Recombinant parainfluenza virus expression systems and vaccines (2007-07-03),

15. 6811784 - Recombinant parainfluenza virus expression system and vaccines (2004-11-02),

Title: Innovations and Contributions of Aurelia Haller

Introduction

Aurelia Haller is a prominent inventor based in Boulder, Colorado, known for her significant contributions to the field of vaccine development and viral research. With a remarkable portfolio of 15 patents, she has made strides in addressing critical health challenges through innovative solutions.

Latest Patents

Among her latest patents is a groundbreaking invention related to metapneumovirus strains and their use in vaccine formulations. This invention provides an isolated mammalian negative strand RNA virus, specifically within the sub-family Pneumoviridae. It also encompasses genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, particularly human metapneumoviruses. Additionally, her work includes the development of yeast-based therapeutics for chronic hepatitis C infection, which involves novel HCV fusion proteins that can be utilized as vaccines or in conjunction with a yeast-based vaccine vehicle.

Career Highlights

Aurelia has worked with notable companies such as Globeimmune, Inc. and Medimmune Vaccines, Inc., where she has contributed her expertise in vaccine research and development. Her innovative approaches have positioned her as a leader in her field, driving advancements in therapeutic solutions.

Collaborations

Throughout her career, Aurelia has collaborated with esteemed colleagues, including Richard C. Duke and Alex Franzusoff. These partnerships have further enhanced her research and development efforts, leading to impactful innovations.

Conclusion

Aurelia Haller's work exemplifies the spirit of innovation in the field of medical research. Her contributions to vaccine development and viral research continue to pave the way for new therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.